{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}],"title":"Achieved > or = PR"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Did not achieve > or = PR"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"(defined as \\> or = to PR) after 4 cycles of response-adapted sequential therapy, using bortezomib and dexamethasone (BD) followed by the addition of lenalidomide in suboptimal responders","groups":[{"description":"This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.\n\nBortezomib: Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\\^2, days 1, 8, 15 and 22\n\nDexamethasone: Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).\n\nLenalidomide: Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression","id":"OG000","title":"Patients With Multiple Myeloma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"after 4 cycles of response-adapted sequential therapy, up to 5 months","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}